Navigation Links
Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
Date:12/1/2008

BASKING RIDGE, N.J., Dec. 1 /PRNewswire/ -- Regado Biosciences, Inc., announced today David J. Mazzo, Ph.D., President and Chief Executive Officer, will present at the 20th Annual Piper Jaffray Health Care Conference in New York, NY, on Tuesday, December 2, 2008, at 10:10am (Eastern Standard Time). Dr. Mazzo will discuss the Company's development pipeline, in addition to reviewing recent business and clinical developments.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.


'/>"/>
SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
2. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
3. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
4. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
5. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
7. BBM Announces Offer to Acquire YM BioSciences Inc.
8. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
9. LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... ... July 08, 2020 , ... Bode Technology, ... expansion of laboratory operations through its COVID-19 testing service, Bode-CARES . Bode-CARES ... , Bode-CARES provides a turnkey solution that includes a comprehensive collection ...
(Date:7/10/2020)... (PRWEB) , ... July 09, 2020 , ... ... called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in zebrafish embryos, ... PolyU research team led by Dr MA has been using the zebrafish model ...
(Date:7/7/2020)... , ... July 06, 2020 , ... R3 International is ... featuring up to 200 million stem cells. Depending on the patient's condition, treatment may ... the US will die having some form of Alzheimers dementia, and the incidence continues ...
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift ... 40% in 2020, despite many obstacles created as a result of COVID-19. As ... for its partnered medical practices and medical manufacturers by expanding access to device ...
Breaking Biology Technology:
(Date:7/22/2020)... ... July 21, 2020 , ... USDM ... technology and compliance, announces a new solution to manage regulated workloads on Microsoft ... of their technology stack complies with FDA and global regulations. USDM's new managed ...
(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics ... recognition and multiple awards for not only the products and treatments developed, but ... and Vivace® Microneedle RF. All the brands built by ABM have received several ...
(Date:6/28/2020)... BASEL, Switzerland (PRWEB) , ... ... ... leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that ... oncology company developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational ...
Breaking Biology News(10 mins):